Belgium's Celyad H1 net loss narrows on lower expenses
Belgium's Celyad H1 net loss narrows on lower expenses
Overview
Belgium biotechnology firm's first half 2026 net loss narrowed on reduced expenses
Company posted no revenue for first half 2026, consistent with prior-year period
Expense reduction driven by workforce cuts, divestments, and cost controls
Outlook
Company projects existing cash will fund estimated expenditures into 2027
Result Drivers
WORKFORCE REDUCTION - Co said lower employee benefit expenses were due to workforce cuts implemented during 2025
DIVESTMENTS - Co said reduced operating expenses reflected strategic divestments, including disposal of R&D facility and catheter business
COST CONTROLS - Co said ongoing cost control measures and lower external service costs contributed to reduced operating expenses
Company press release: ID:nBwlq7MTa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Net Loss |
| EUR 1.20 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Reuters Recommended Reads
Sept 22 - Celldex shares slip as safety concerns cloud skin drug trial win
Sept 22 - Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Sept 21 - France's Abivax H1 net loss widens on higher expenses driven by clinical programs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)